My NCBI | Sign In
RSS Settings
  • Search: Banikazemi M[au]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 23

    1.

    Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry.

    Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P.

    Genet Med. 2009 Nov;11(11):790-6.PMID: 19745746 [PubMed - in process]Related articles

    2.

    Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy.

    Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, Sorensen SA, Wilcox WR, Desnick RJ.

    Nephrol Dial Transplant. 2009 Jul;24(7):2102-11. Epub 2009 Feb 13.PMID: 19218538 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry.

    Sims K, Politei J, Banikazemi M, Lee P.

    Stroke. 2009 Mar;40(3):788-94. Epub 2009 Jan 15.PMID: 19150871 [PubMed - indexed for MEDLINE]Related articles

    4.

    Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry.

    Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, Lemay R, Tylki-Szymanska A, Wilcox WR.

    Pediatr Res. 2008 Nov;64(5):550-5.PMID: 18596579 [PubMed - indexed for MEDLINE]Related articles

    5.

    Home-based infusion therapy for patients with Fabry disease.

    Cousins A, Lee P, Rorman D, Raas-Rothschild A, Banikazemi M, Waldek S, Thompson L.

    Br J Nurs. 2008 May 22-Jun 11;17(10):653-7. Review.PMID: 18563007 [PubMed - indexed for MEDLINE]Related articles

    6.

    Prevalence of type 1 Gaucher disease in the United States.

    Weinreb NJ, Andersson HC, Banikazemi M, Barranger J, Beutler E, Charrow J, Grabowski GA, Hollak CE, Kaplan P, Mankin H, Mistry PK, Rosenbloom BE, Vom Dahl S, Zimran A.

    Arch Intern Med. 2008 Feb 11;168(3):326-7; author reply 327-8. No abstract available. PMID: 18268176 [PubMed - indexed for MEDLINE]Related articles

    7.

    Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.

    Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP; Fabry Registry.

    Mol Genet Metab. 2008 Feb;93(2):112-28. Epub 2007 Nov 26.PMID: 18037317 [PubMed - indexed for MEDLINE]Related articles

    8.

    Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.

    Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N.

    J Am Soc Nephrol. 2007 May;18(5):1547-57. Epub 2007 Apr 4.PMID: 17409312 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.

    Desnick RJ, Banikazemi M.

    Nephrol Ther. 2006 Jan;2 Suppl 2:S172-85.PMID: 17373219 [PubMed - indexed for MEDLINE]Related articles

    10.

    Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry.

    Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, Breunig F, Charrow J, Germain DP, Nicholls K, Banikazemi M.

    J Inherit Metab Dis. 2007 Apr;30(2):184-92. Epub 2007 Mar 8.PMID: 17347915 [PubMed - indexed for MEDLINE]Related articles

    11.

    Agalsidase-beta therapy for advanced Fabry disease: a randomized trial.

    Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ; Fabry Disease Clinical Trial Study Group.

    Ann Intern Med. 2007 Jan 16;146(2):77-86. Epub 2006 Dec 18.PMID: 17179052 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Fabry disease: guidelines for the evaluation and management of multi-organ system involvement.

    Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR.

    Genet Med. 2006 Sep;8(9):539-48. Review.PMID: 16980809 [PubMed - indexed for MEDLINE]Related articles

    13.

    Does enzyme replacement therapy improve symptoms of Fabry disease in patients undergoing dialysis?

    Banikazemi M, Desnick RJ.

    Nat Clin Pract Nephrol. 2006 Feb;2(2):72-3. No abstract available. PMID: 16932395 [PubMed - indexed for MEDLINE]Related articles

    14.

    Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome.

    Nance CS, Klein CJ, Banikazemi M, Dikman SH, Phelps RG, McArthur JC, Rodriguez M, Desnick RJ.

    Arch Neurol. 2006 Mar;63(3):453-7.PMID: 16533976 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.

    Banikazemi M, Ullman T, Desnick RJ.

    Mol Genet Metab. 2005 Aug;85(4):255-9.PMID: 15939645 [PubMed - indexed for MEDLINE]Related articles

    16.

    Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.

    Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP; International Fabry Disease Study Group.

    Am J Hum Genet. 2004 Jul;75(1):65-74. Epub 2004 May 20.PMID: 15154115 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Fabry disease: renal sonographic and magnetic resonance imaging findings in affected males and carrier females with the classic and cardiac variant phenotypes.

    Glass RB, Astrin KH, Norton KI, Parsons R, Eng CM, Banikazemi M, Desnick RJ.

    J Comput Assist Tomogr. 2004 Mar-Apr;28(2):158-68.PMID: 15091117 [PubMed - indexed for MEDLINE]Related articles

    18.

    Enzyme replacement therapy for Fabry disease, an inherited nephropathy.

    Desnick RJ, Banikazemi M, Wasserstein M.

    Clin Nephrol. 2002 Jan;57(1):1-8. Review.PMID: 11837797 [PubMed - indexed for MEDLINE]Related articles

    19.

    Fabry disease (alpha-galactosidase A deficiency): renal involvement and enzyme replacement therapy.

    Desnick RJ, Wasserstein MP, Banikazemi M.

    Contrib Nephrol. 2001;(136):174-92. Review. No abstract available. PMID: 11688379 [PubMed - indexed for MEDLINE]Related articles

    20.

    A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies.

    Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, Gass A, Winston J, Dikman S, Fallon JT, Brodie S, Stacy CB, Mehta D, Parsons R, Norton K, O'Callaghan M, Desnick RJ.

    Am J Hum Genet. 2001 Mar;68(3):711-22. Epub 2001 Feb 1.PMID: 11179018 [PubMed - indexed for MEDLINE]Related articlesFree article

    21.

    Mutations in a new gene encoding a thiamine transporter cause thiamine-responsive megaloblastic anaemia syndrome.

    Diaz GA, Banikazemi M, Oishi K, Desnick RJ, Gelb BD.

    Nat Genet. 1999 Jul;22(3):309-12.PMID: 10391223 [PubMed - indexed for MEDLINE]Related articles

    22.

    Localization of the thiamine-responsive megaloblastic anemia syndrome locus to a 1.4-cM region of 1q23.

    Banikazemi M, Diaz GA, Vossough P, Jalali M, Desnick RJ, Gelb BD.

    Mol Genet Metab. 1999 Mar;66(3):193-8.PMID: 10066388 [PubMed - indexed for MEDLINE]Related articles

    23.

    Review: borders, patterns, and distinctive families of homeodomains.

    Gindilis V, Banikazemi M, Vyasankin A, Verlinsky O, Matveyev I, Verlinsky Y.

    J Assist Reprod Genet. 1994 May;11(5):244-69. Review.PMID: 7711388 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    3 free full-text articles in PubMed Central

    Find related data

    Search details

    » See more...

    Recent activity